and ICH guidelines.

2. Scope

This SOP applies to formulation scientists, R&D chemists, and quality assurance personnel involved in designing, optimizing, and validating IO injectable formulations in a sterile manufacturing setting.

3. Responsibilities

• Formulation Scientist: Designs formulation, performs risk assessment, and defines quality attributes.
• R&D Chemist: Prepares trial formulations and supports scale-up.
• QA Officer: Reviews records and ensures GMP compliance.
• Stability Analyst: Conducts accelerated and real-time stability studies.

4. Accountability

The Head of R&D is accountable for ensuring compliance with regulatory standards and for the successful development of safe and effective IO formulations.

5. Procedure

5.1 Pre-formulation Studies

1. Review API properties: solubility, pKa, hygroscopicity, stability in aqueous solution.
2. Determine target volume for IO injection (ideally ≤ 5 mL per site).
3. Assess injection force tolerance to avoid pressure damage to bone tissue.

5.2 Excipients Selection

1. Use only parenteral-grade, pharmacopeia-compliant excipients:
   • Buffers (e.g., citrate or phosphate)
   • Stabilizers (e.g., EDTA, polysorbates)
   • Isotonic agents (e.g., mannitol, dextrose)
2. Excipient concentration must not interfere with hematopoietic tissue.

5.3 Formulation Design

1. Target osmolarity: 270–310 mOsm/kg
2. pH range: 6.5–7.5 (close to physiological pH)
3. Formulations must be isotonic, non-pyrogenic, and sterile
4. Use WFI (Water for Injection) as the vehicle

5.4 Trial Batch Preparation

1. Prepare trial batches using aseptic technique in Grade B environment.
2. Sterile filter (0.22 µm) and fill into Type I glass ampoules or vials.
3. Visually inspect filled containers for clarity and particles.

5.5 Stability Studies

1. Label and place samples on:
   • Accelerated conditions: 40°C / 75% RH
   • Long-term: 25°C / 60% RH
2. Test for:
   • Assay and degradation products
   • pH, osmolality, particulate matter
   • Sterility and endotoxins

5.6 Documentation

1. Record all batch details in Formulation Development Report (Annexure-2).
2. Include a Justification Report for excipient selection (Annexure-3).

6. Abbreviations

• IO: Intraosseous
• API: Active Pharmaceutical Ingredient
• GMP: Good Manufacturing Practices
• ICH: International Council for Harmonisation
• WFI: Water for Injection

7. Documents

1. Stability Testing Plan – Annexure-1
2. Formulation Development Report – Annexure-2
3. Excipient Justification Report – Annexure-3

8. References

• ICH Q8 (R2) – Pharmaceutical Development
• ICH Q1A (R2) – Stability Testing
• USP <788> – Particulate Matter in Injections

9. SOP Version

Version: 2.0

10. Approval Section

	Prepared By	Checked By	Approved By
Signature
Date
Name
Designation	Formulation Scientist	QA Manager	Head – R&D
Department	R&D	Quality Assurance	Formulation Development

11. Annexures

Annexure-1: Stability Testing Plan

Batch ID	Condition	Duration	Test Parameter	Analyst
IO-B-101	40°C / 75% RH	1M	Assay, pH	Sunita Reddy

Annexure-2: Formulation Development Report

Product	Intraosseous Injection – API Z
Batch No.	IO-DEV-002
Formulated By	Rajesh Kumar
Date	10/06/2025

Annexure-3: Excipient Justification Report

Excipient	Function	Justification
Citrate Buffer	pH control	Maintains compatibility with bone environment
Mannitol	Isotonic agent	Ensures osmotic balance

Revision History

Revision Date	Revision No.	Details	Reason	Approved By
05/03/2022	1.0	Initial Version	New Product Line	QA Head
18/06/2025	2.0	Enhanced formulation parameters and annexures added	Annual SOP Review	QA Head